Health
U.S. Dominates Global Cancer Research Funding, EU Ramps Up Spending
A new international analysis has found that the United States remains the dominant force in global cancer research funding, while the European Union is steadily increasing its share. The findings, published in The Lancet Oncology, examined nearly 108,000 research awards made worldwide between 2016 and 2023, totalling $51.4 billion (€44 billion).
The study, which covered government and philanthropic contributions but excluded private sector investment, showed the U.S. accounted for 57% of all spending, equivalent to €25.2 billion. The European Union and its member states provided 16.8% (€7.4 billion), while the United Kingdom contributed 11.1% (€4.9 billion).
Other notable contributors included Japan (3.6%, or €1.6 billion), Australia (2.9%, or €1.3 billion), and both Canada and China, each with 2.6% (€1.3 billion).
EU Investment Rising Despite Global Decline
The report highlighted that global investment in cancer research fell each year of the study period except 2021, when funding spiked before declining again. The EU was a notable exception, continuing to increase its funding levels, largely driven by Germany, which invested €610 million over the period.
Michael Head, the study’s lead author and a senior research fellow at the University of Southampton, stressed the importance of tracking where resources are directed. “It’s crucial we understand how and where money is allocated,” he said.
Uneven Global Investment
The analysis underscored stark disparities in research investment between high-income and low-income nations. Wealthy countries contributed the overwhelming majority of funds, typically investing within their own borders, while lower-income countries collectively accounted for just €48.4 million over the eight years.
Researchers warned that the gap could worsen, pointing to potential consequences of U.S. funding cuts during the Trump administration, which had threatened to slow international collaboration.
Priorities and Gaps in Research
The study also revealed how funding was distributed across cancer types and treatment approaches. Around 76% of global cancer research money went to laboratory-based projects, with breast cancer, blood cancers, and clinical trials among the most heavily funded areas.
By contrast, research into cancer surgery and radiotherapy—two of the most widely used treatment methods—was described as “severely underfunded.” This imbalance, the authors warned, risks leaving vital aspects of cancer care underdeveloped.
A Growing Global Burden
According to the World Health Organization, cancer is responsible for one in six deaths worldwide. The burden is growing as populations age, with low- and middle-income countries facing some of the highest risks due to limited access to timely diagnosis and treatment.
“Inequalities in investment across nations, and low research funding for certain treatments, can lead to an imbalance in the cancers we can tackle and the areas of the world benefiting,” Head said.
The findings suggest that while cancer research funding remains concentrated in a handful of wealthy nations, rising investment in Europe may signal a shift in global priorities.
-
Entertainment2 years agoMeta Acquires Tilda Swinton VR Doc ‘Impulse: Playing With Reality’
-
Business2 years agoSaudi Arabia’s Model for Sustainable Aviation Practices
-
Business2 years agoRecent Developments in Small Business Taxes
-
Sports2 years agoChina’s Historic Olympic Victory Sparks National Pride Amid Controversy
-
Home Improvement1 year agoEffective Drain Cleaning: A Key to a Healthy Plumbing System
-
Politics2 years agoWho was Ebrahim Raisi and his status in Iranian Politics?
-
Sports2 years agoKeely Hodgkinson Wins Britain’s First Athletics Gold at Paris Olympics in 800m
-
Business2 years agoCarrectly: Revolutionizing Car Care in Chicago
